Transplantation of a combination of CD133+ and CD34+ selected progenitor cells from alternative donors

被引:75
|
作者
Lang, P
Bader, P
Schumm, M
Feuchtinger, T
Einsele, H
Führer, M
Weinstock, C
Handgretinger, R
Kuci, S
Martin, D
Niethammer, D
Greil, J
机构
[1] Univ Tubingen, Univ Childrens Hosp, Dept Pediat Oncol, D-72076 Tubingen, Germany
[2] Univ Tubingen, Dept Internal Med, Tubingen, Germany
[3] Univ Munich, Childrens Univ Hosp, Munich, Germany
[4] Univ Tubingen, Dept Transfus Med, Tubingen, Germany
[5] St Jude Childrens Res Hosp, Memphis, TN 38105 USA
关键词
stem cell transplantation; alternative donors; CD34(+) selection; CD133(+)-selection; haploidentical;
D O I
10.1046/j.1365-2141.2003.04747.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Positive selected haematopoietic stem cells are increasingly used for allogeneic transplantation with the CD34 antigen employed in most separation techniques. However, the recently described pentaspan molecule CD133 appears to be a marker of more primitive haematopoietic progenitors. Here we report our experience with a new CD133-based selection method in 10 paediatric patients with matched unrelated (n = 2) or mismatched-related donors (n = 8). These patients received a combination of stem cells (median = 29.3 x 10(6)/kg), selected with either anti-CD34 or anti-CD133 coated microbeads. The proportion of CD133(+) selected cells was gradually increased from patient to patient from 10% to 100%. Comparison of CD133(+) and CD34(+) separation procedures revealed similar purity and recovery of target populations but a lower depletion of T cells by CD133(+) selection (3.7 log vs. 4.1 log, P < 0.001). Both separation procedures produced >90% CD34(+)/CD133(+) double positive target cells. Engraftment occurred in all patients (sustained primary, n = 8; after reconditioning, n = 2). No primary acute graft versus host disease (GvHD) greater than or equal to grade II or chronic GvHD was observed. The patients showed a rapid platelet recovery (median time to independence from substitution = 13.5 d), whereas T cell regeneration was variable. Five patients are alive with a median follow-up of 10 months. Our data demonstrates the feasibility of CD133(+) selection for transplantation from alternative donors and encourages further trials with total CD133(+) separated grafts.
引用
收藏
页码:72 / 79
页数:8
相关论文
共 50 条
  • [21] Combined Characterization of microRNa and mRNa Profiles Delineates Early Differentiation Pathways of CD133+ and CD34+ Hematopoietic Stem and Progenitor Cells
    Bissels, Ute
    Wild, Stefan
    Tomiuk, Stefan
    Hafner, Markus
    Scheel, Hartmut
    Mihailovic, Aleksandra
    Choi, Yeong-Hoon
    Tuschl, Thomas
    Bosio, Andreas
    STEM CELLS, 2011, 29 (05) : 847 - 857
  • [22] CD133+ hepatic stellate cells are progenitor cells
    Kordes, Claus
    Sawitza, Iris
    Mueller-Marbach, Alexis
    Ale-Agha, Niloofar
    Keitel, Verena
    Klonowski-Stumpe, Hanne
    Haeussinger, Dieter
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 352 (02) : 410 - 417
  • [23] Transplantation of CD133+ selected haploidentical hematopoietic stem cells.
    Greil, J
    Lang, PJ
    Schumm, M
    Bader, P
    Kuqi, S
    Gordon, P
    Handgretinger, R
    Niethammer, D
    BLOOD, 2002, 100 (11) : 637A - 637A
  • [24] Long-term Prediction of Cardiovascular Outcomes by Circulating CD34+ and CD34+ CD133+ Stem Cells in Patients With Type 2 Diabetes
    Fadini, Gian Paolo
    Rigato, Mauro
    Cappellari, Roberta
    Bonora, Benedetta Maria
    Avogaro, Angelo
    DIABETES CARE, 2017, 40 (01) : 125 - 131
  • [25] Stem cells in T-ALL have a primitive CD133+/CD34+/CD7-phenotype.
    Cox, CV
    Evely, RS
    Goulden, NJ
    Blair, A
    BLOOD, 2004, 104 (11) : 522A - 522A
  • [26] POSITIVE SELECTION OF CD34+ HEMATOPOIETIC PROGENITOR CELLS FOR TRANSPLANTATION
    SHPALL, EJ
    JONES, RB
    BEARMAN, SI
    STEMMER, SM
    PURDY, MH
    HEIMFELD, S
    BERENSON, RJ
    STEM CELLS, 1993, 11 : 48 - 49
  • [27] ARRAY BASED ANALYSIS OF MIRNA AND MRNA EXPRESSION CHARACTERIZES EARLY DIFFERENTIATION PATHWAYS OF CD133+ AND CD34+ HEMATOPOIETIC STEM AND PROGENITOR CELLS
    Bissels, U.
    Wild, S.
    Tomiuk, S.
    Hafner, M.
    Scheel, H.
    Mihailovic, A.
    Choi, Y.
    Tuschl, T.
    Bosio, A.
    EXPERIMENTAL HEMATOLOGY, 2011, 39 (08) : S57 - S58
  • [28] Platelet released growth factors boost expansion of bone marrow derived CD34+ and CD133+ endothelial progenitor cells for autologous grafting
    Lippross, Sebastian
    Loibl, Markus
    Hoppe, Sven
    Meury, Thomas
    Benneker, Lorin
    Alini, Mauro
    Verrier, Sophie
    PLATELETS, 2011, 22 (06) : 422 - 432
  • [29] Hypoxia-induced differential expression of angiogenesis genes by umbilical cord blood-derived CD34+/CD133+ progenitor cells
    Gaballa, MA
    Khailova, L
    Goldman, S
    Thai, H
    Harris, D
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2006, 47 (04) : 191A - 191A
  • [30] FUNCTIONAL ANALYSES OF HUMAN HEMATOPOIETIC CD133+CD34+ AND CD133LOW/-CD34+ CELLS CHALLENGE THE EXISTENCE OF HUMAN COMMON MYELOID PROGENITOR CELLS
    Goergens, Andre
    Radtke, Stefan
    Moellmann, Michael
    Duerig, Jan
    Horn, Peter
    Giebel, Bernd
    EXPERIMENTAL HEMATOLOGY, 2012, 40 (08) : S124 - S124